Keywords
Oral squamous cell carcinoma (OSCC)
4-nitroquinoline 1-oxide (4-NQO)
Peripheral blood mononuclear cell (PBMC)
Enzyme-linked immunosorbent assay (ELISA)
Submitted : 2024-08-27
Accepted : 2024-09-11
Published : 2024-09-26
Abstract
Objective: This investigation delineates the anti-cancer potency of epigallocatechin-3-gallate (EGCG) in an oral cancer mouse model, with a focus on its effect on T-cell activation. Methods: An oral cancer model was established in male Balb/c mice using 4-nitroquinoline 1-oxide (4-NQO). The mice were systematically grouped and administered graded concentrations of EGCG. Key parameters such as body weight, hydration levels, tumor volume, and mass were meticulously tracked. T-cell activity and cytokine expression profiles, focusing on interleukin-2 (IL-2), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α), were quantified using ELISA. A comprehensive statistical evaluation included one-way ANOVA, Tukey’s HSD multiple comparison test, and the Kruskal-Wallis non-parametric assessment. Results: EGCG-administered cohorts exhibited a pronounced reduction in tumor size and mass, with the high-dose group showing the greatest efficacy. ELISA findings corroborated a significant increase in T-cell activity and concomitant upregulation of key cytokines, including IL-2, IFN-γ, and TNF-α (P < 0.05). Conclusion: This investigation confirms the tumor-suppressive efficacy of EGCG in a murine oral squamous cell carcinoma model. The therapeutic effects of EGCG are mediated through T-cell activation and the upregulation of pivotal cytokine expression, highlighting its potential immunomodulatory role in oral cancer treatment.
References
Sung H, Ferlay J, Siegel RL, et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3): 209–249. https://doi.org/10.3322/caac.21660
Fang Y, Yu Y, Wu DW, et al., 2020, A Review of Immune-Related Adverse Events Associated with Immunotherapy. Zhonghua Zhong Liu Za Zhi, 42(1): 17–21. https://doi.org/10.3760/cma.j.issn.0253-3766.2020.01.002
Ferrari E, Bettuzzi S, Naponelli V, 2022, The Potential of Epigallocatechin Gallate (EGCG) in Targeting Autophagy for Cancer Treatment: A Narrative Review. Int J Mol Sci, 23(11): 6075. https://doi.org/10.3390/ijms23116075
Aggarwal V, Tuli HS, Tania M, et al., 2022, Molecular Mechanisms of Action of Epigallocatechin Gallate in Cancer: Recent Trends and Advancement. Semin Cancer Biol, 80: 256–275. https://doi.org/10.1016/j.semcancer.2020.05.011
Rawangkan A, Wongsirisin P, Namiki K, et al., 2018, Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth. Molecules, 23(8): 2071. https://doi.org/10.3390/molecules23082071
Xiao X, Jiang K, Xu Y, et al., 2019, (-)-Epigallocatechin-3-Gallate Induces Cell Apoptosis in Chronic Myeloid Leukaemia by Regulating Bcr/Abl-Mediated p38-MAPK/JNK and JAK2/STAT3/AKT Signalling Pathways. Clin Exp Pharmacol Physiol, 46(2): 126–136. https://doi.org/10.1111/1440-1681.13037
Huang SC, Kao YH, Shih SF, et al., 2021, Epigallocatechin-3-Gallate Exhibits Immunomodulatory Effects in Human Primary T Cells. Biochem Biophys Res Commun, 550: 70–76. https://doi.org/10.1016/j.bbrc.2021.02.132
Pan Y, Long X, Yi R, et al., 2018, Polyphenols in Liubao Tea Can Prevent CCl4-Induced Hepatic Damage in Mice through Its Antioxidant Capacities. Nutrients, 10(9): 1280. https://doi.org/10.3390/nu10091280
Shen H, Wu N, Liu Z, et al., 2017, Epigallocatechin-3-Gallate Alleviates Paraquat-Induced Acute Lung Injury and Inhibits Upregulation of Toll-Like Receptors. Life Sci, 170: 25–32. https://doi.org/10.1016/j.lfs.2016.11.021
Luo KW, Lung WY, Chun X, et al., 2018, EGCG Inhibited Bladder Cancer T24 and 5637 Cell Proliferation and Migration via PI3K/AKT Pathway. Oncotarget, 9(15): 12261–12272. https://doi.org/10.18632/oncotarget.24301
Zhou CG, Hui LM, Luo JM, 2018, Epigallocatechin Gallate Inhibits the Proliferation and Induces Apoptosis of Multiple Myeloma Cells via Inactivating EZH2. Eur Rev Med Pharmacol Sci, 22(7): 2093–2098. https://doi.org/10.26355/eurrev_201804_14742
Luo KW, Wei C, Lung WY, et al., 2017, EGCG Inhibited Bladder Cancer SW780 Cell Proliferation and Migration Both In Vitro and In Vivo via Down-Regulation of NF-KappaB and MMP-9. J Nutr Biochem, 41: 56–64. https://doi.org/10.1016/j.jnutbio.2016.12.004. Erratum in J Nutr Biochem, 123: 109530. https://doi.org/10.1016/j.jnutbio.2023.109530
Zhao J, Blayney A, Liu X, et al., 2021, EGCG Binds Intrinsically Disordered N-Terminal Domain of p53 and Disrupts p53-MDM2 Interaction. Nat Commun, 12(1): 986. https://doi.org/10.1038/s41467-021-21258-5